Vertex (VRTX): Q3 2026 sales top estimates, EPS slightly below
FROM THE WIRE · FINANCE.YAHOO.COM
Vertex Pharmaceuticals's (NASDAQ:VRTX) Q3 2026 sales top estimates Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market's revenue expectations , with revenue up 11.8% year on year to $3.44 billion. On the other hand, the company's…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralRevenue beat but EPS and annual guidance slightly below consensus make the picture mixed for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Revenue was 3.44 billion dollars, up 11.8% year on year.
- 02The full-year revenue guidance midpoint of 13.2 billion dollars is 0.6% below consensus.
- 03Adjusted EPS of 4.76 dollars was 0.5% below analysts' consensus estimates.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets